TABLE 4.
Antiviral activity of ombitasvir in transient assays with HCV replicons containing NS5A genes from treatment-naive HCV-infected patients
| Genotype | No. isolates | EC50 (pM) |
|
|---|---|---|---|
| Range | Mean ± SDa | ||
| 1a | 11 | 0.35–0.88 | 0.66 ± 0.14 |
| 1b | 11 | 0.74–1.5 | 1.0 ± 0.23 |
| 2ab | 9 | 0.87–11 | 3.9 ± 3.0 |
| 2bc | 14 | 0.54–45 | 1.1 ± 1.2 |
| 3a | 13 | 0.90–55 | 4.5 ± 4.3 |
| 4ad | 9 | 0.10–0.36 | 0.24 ± 0.08 |
| 5a | 1 | 0.67 | |
| 6ae | 2 | 42–68 | 55 ± 18 |
a
Outliers due to presence of known resistance-associated variants were excluded when calculating the mean EC50s.
b
All the genotype 2a isolates had M31.
c
Of the genotype 2b isolates, 8 had L31 and 6 had M31.
d
Two of the genotype 4a isolates had M28 and 7 had L28.
e
Only 1 genotype 6a isolate was available. L28F, a common polymorphism, was introduced into this isolate.